These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31257722)

  • 1. National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.
    Hartshorn CM; Russell LM; Grodzinski P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Nov; 11(6):e1570. PubMed ID: 31257722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCI Alliance for Nanotechnology in Cancer - from academic research to clinical interventions.
    Grodzinski P; Liu CH; Hartshorn CM; Morris SA; Russell LM
    Biomed Microdevices; 2019 Mar; 21(2):32. PubMed ID: 30904965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Nanotechnology into Cancer Care.
    Grodzinski P; Kircher M; Goldberg M; Gabizon A
    ACS Nano; 2019 Jul; 13(7):7370-7376. PubMed ID: 31240914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NCI Alliance for Nanotechnology in Cancer: achievement and path forward.
    Ptak K; Farrell D; Panaro NJ; Grodzinski P; Barker AD
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):450-60. PubMed ID: 20552623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer.
    Farrell D; Alper J; Ptak K; Panaro NJ; Grodzinski P; Barker AD
    ACS Nano; 2010 Feb; 4(2):589-94. PubMed ID: 20175564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.
    Hartshorn CM; Bradbury MS; Lanza GM; Nel AE; Rao J; Wang AZ; Wiesner UB; Yang L; Grodzinski P
    ACS Nano; 2018 Jan; 12(1):24-43. PubMed ID: 29257865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highlights of recent developments and trends in cancer nanotechnology research--view from NCI Alliance for Nanotechnology in Cancer.
    Hull LC; Farrell D; Grodzinski P
    Biotechnol Adv; 2014; 32(4):666-78. PubMed ID: 23948249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current landscape of treating different cancers using nanomedicines: Trends and perspectives.
    Morales CS; Grodzinski P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1927. PubMed ID: 37706362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology-based cancer therapeutics--promise and challenge--lessons learned through the NCI Alliance for Nanotechnology in Cancer.
    Farrell D; Ptak K; Panaro NJ; Grodzinski P
    Pharm Res; 2011 Feb; 28(2):273-8. PubMed ID: 20814720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering and physical sciences in oncology: challenges and opportunities.
    Mitchell MJ; Jain RK; Langer R
    Nat Rev Cancer; 2017 Nov; 17(11):659-675. PubMed ID: 29026204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future opportunities in cancer nanotechnology--NCI strategic workshop report.
    Grodzinski P; Farrell D
    Cancer Res; 2014 Mar; 74(5):1307-10. PubMed ID: 24413533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging implications of nanotechnology on cancer diagnostics and therapeutics.
    Cuenca AG; Jiang H; Hochwald SN; Delano M; Cance WG; Grobmyer SR
    Cancer; 2006 Aug; 107(3):459-66. PubMed ID: 16795065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of nanotechnology in cancer research: review of progress in the National Cancer Institute's Alliance for Nanotechnology.
    Ehdaie B
    Int J Biol Sci; 2007 Jan; 3(2):108-10. PubMed ID: 17304339
    [No Abstract]   [Full Text] [Related]  

  • 14. A boost for the emerging field of RNA nanotechnology.
    Shukla GC; Haque F; Tor Y; Wilhelmsson LM; Toulmé JJ; Isambert H; Guo P; Rossi JJ; Tenenbaum SA; Shapiro BA
    ACS Nano; 2011 May; 5(5):3405-18. PubMed ID: 21604810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.
    Zamboni WC; Torchilin V; Patri AK; Hrkach J; Stern S; Lee R; Nel A; Panaro NJ; Grodzinski P
    Clin Cancer Res; 2012 Jun; 18(12):3229-41. PubMed ID: 22669131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dartmouth Center for Cancer Nanotechnology Excellence: magnetic hyperthermia.
    Baker I; Fiering SN; Griswold KE; Hoopes PJ; Kekalo K; Ndong C; Paulsen K; Petryk AA; Pogue B; Shubitidze F; Weaver J
    Nanomedicine (Lond); 2015; 10(11):1685-92. PubMed ID: 26080693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Translation of the National Institutes of Health's Investments in Nanodrug Products and Devices.
    Henderson LA; Shankar LK
    AAPS J; 2017 Mar; 19(2):343-359. PubMed ID: 27995455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The solid progress of nanomedicine.
    Martins JP; das Neves J; de la Fuente M; Celia C; Florindo H; Günday-Türeli N; Popat A; Santos JL; Sousa F; Schmid R; Wolfram J; Sarmento B; Santos HA
    Drug Deliv Transl Res; 2020 Jun; 10(3):726-729. PubMed ID: 32141035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kindling translational cancer nanotechnology research.
    Chapman S; Panaro NJ; Hinkal GW; Hook SS; Prabhakar U; Ptak K; Farrell D; Grodzinski P
    Nanomedicine (Lond); 2012 Mar; 7(3):321-5. PubMed ID: 22385196
    [No Abstract]   [Full Text] [Related]  

  • 20. Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and nanotechnology characterization laboratory.
    Ke W; Crist RM; Clogston JD; Stern ST; Dobrovolskaia MA; Grodzinski P; Jensen MA
    Adv Drug Deliv Rev; 2022 Dec; 191():114591. PubMed ID: 36332724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.